In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cellect Biotechnology Ltd (NASDAQ: APOP), with a price target of $14. The company’s shares closed yesterday at $7.20, close to its 52-week low of $6.12.
“Valuation methodology, risks and uncertainties. We value Cellect based on a discounted cash flow (DCF) approach that assigns a total value of $120M to Cellect’s platform. Our valuation translates into a price per ADS of $14.00, taking into account roughly 8.4M fully-diluted ADSs outstanding as of mid-2019.”
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -0.8% and a 40.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cellect Biotechnology Ltd with a $14 average price target.
Based on Cellect Biotechnology Ltd’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $1.03 million. In comparison, last year the company had a GAAP net loss of $1.3 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection.